1256966-02-5 Usage
Description
Bis(((R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl) hydrogen phosphate, also known as bis-Tedizolidyl Phosphate Diester, is a complex organic compound with a unique structure that features a phosphate group and two tedizolidine rings. This molecule exhibits potent antibacterial properties, making it a promising candidate for pharmaceutical applications.
Uses
Used in Pharmaceutical Industry:
Bis(((R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl) hydrogen phosphate is used as an antibacterial drug for treating or preventing bacterial infections in mammals. Its unique structure and potent antibacterial activity make it a valuable asset in the development of new antibiotics to combat drug-resistant bacteria.
Check Digit Verification of cas no
The CAS Registry Mumber 1256966-02-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,6,9,6 and 6 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1256966-02:
(9*1)+(8*2)+(7*5)+(6*6)+(5*9)+(4*6)+(3*6)+(2*0)+(1*2)=185
185 % 10 = 5
So 1256966-02-5 is a valid CAS Registry Number.
1256966-02-5Relevant articles and documents
OXAZOLIDINONE CONTAINING DIMER COMPOUNDS, COMPOSITIONS AND METHODS TO MAKE AND USE
-
Page/Page column 23; 24, (2010/12/26)
Dosage forms or pharmaceutical compositions comprise a compound having the structure of Formula (IV) wherein n is a non-negative integer; wherein each Z is an oxazolidinone-containing moiety having antibiotic activity in vivo upon cleaving, wherein M is independently OR1 or NR1R2; wherein R1 and R2 are independently selected from the group consisting of H, an optionally-substituted hydrocarbyl residue or a pharmaceutically acceptable cation; wherein the compound in the dosage form or a pharmaceutical composition is present in an amount effective for treating or preventing an antibacterial infection in a mammalian subject. Methods of preparing and using these dosage forms or pharmaceutical compositions are also disclosed.
